New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:48 EDTQ, CVD, AZN, PRXL, CRL, PFE, ICLRCROs sold off on unknowns from potential merger, says Jefferies
Jefferies attributes yesterday's sell-off in the Contract Research Organization space to the potential merger between Pfizer (PFE) and AstraZeneca (AZN) and the fear or other large pharma deals. The firm believes current share levels will prove attractive entry points over a three-year time frame. It notes Charles River Labs (CRL) and PAREXEL (PRXL) have the greatest exposure to the potential takeover of AstraZeneca while Covance (CVD) is less exposed. Other names in the CRO sector include ICON plc (ICLR) and Quintiles (Q).
News For CRL;CVD;ICLR;PRXL;Q;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
10:48 EDTAZNShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
06:33 EDTCRLCharles River Labs upgraded to Buy from Neutral at SunTrust
SunTrust upgraded Charles River Labs to Buy and raised estimates to reflect DSA segment revenue growth, an early stage industry recovery that creates long-term performance potential, and views valuation as attractive. Price target is $70.
October 14, 2014
11:23 EDTAZN, PFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 10, 2014
10:01 EDTPRXL, ICLROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:01 EDTQOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
07:57 EDTPRXLPAREXEL downgraded at ISI Group
Subscribe for More Information
07:57 EDTQQuintiles upgraded at ISI Group
As previously reported, ISI Group upgraded Quintiles to Buy from Neutral. The firm sees further upside to shares driven by market product development growth, effective capital deployment, and an improving outlook for IHS. Price target is $61.
07:50 EDTICLRICON plc downgraded to Neutral from Buy at ISI Group
As previously reported, ISI Group downgraded ICON plc to Neutral from Buy. The firm downgraded shares based on valuation and lack of near-term catalysts. Price target is $62.
06:19 EDTICLRICON plc downgraded to Neutral from Buy at ISI Group
06:19 EDTQQuintiles upgraded to Buy from Neutral at ISI Group
Subscribe for More Information
06:18 EDTPRXLPAREXEL downgraded to Neutral from Buy at ISI Group
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use